Schroder Investment Management Group’s Regulus Therapeutics RGLS Stock Holding History

Schroder Investment Management Group’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-917	Closed	-$363K	–	1182
2016 Q3	$363K	Hold	917	–	–	﹤0.01%	997
2016 Q2	$318K	Hold	917	–	–	﹤0.01%	996
2016 Q1	$720K	Buy	917 +605	+194%	+$481K	﹤0.01%	947
2015 Q4	$327K	Hold	312	–	–	﹤0.01%	1010
2015 Q3	$245K	Hold	312	–	–	﹤0.01%	1014
2015 Q2	$379K	Hold	312	–	–	﹤0.01%	998
2015 Q1	$631K	Sell	312 -243	-44%	-$528K	﹤0.01%	983
2014 Q4	$1.07M	Sell	555 -634	-53%	-$1.13M	﹤0.01%	989
2014 Q3	$974K	Buy	+1,189	New	+$1.01M	﹤0.01%	1014

Other funds holding RGLS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SDIC

South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Schroder Investment Management Group's RGLS Position: Q4 2016 in Review

Schroder Investment Management Group sold out of Regulus Therapeutics (RGLS) in Q4 2016, closing a stake of 917 shares — an estimated $363K sold.

Schroder Investment Management Group first reported a position in RGLS in Q3 2014 and held it in 9 quarters. The position peaked at $1.07M in Q4 2014. 68 funds tracked by Wall St. Rank hold RGLS as of Q4 2016.

Schroder Investment Management Group reported no remaining Regulus Therapeutics position as of Q4 2016 after selling out during the quarter.
Schroder Investment Management Group sold 917 Regulus Therapeutics shares in Q4 2016, an estimated $363K.
Schroder Investment Management Group first reported a position in Regulus Therapeutics in Q3 2014 and held it in 9 quarters.
Schroder Investment Management Group's Regulus Therapeutics position peaked at $1.07M in Q4 2014.
68 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2016.

Based on Schroder Investment Management Group's 13F filing for Q4 2016, filed 10 Feb 2017.